Charles River Laboratories International Inc was incorporated in 1994 in Delaware and in 2000, it completed its initial public offering. It is a full service, early-stage contract research organization. The Company's portfolio includes research models and services required to enabling vivo drug discovery and development. Discovery represents the earliest stages of research in the life sciences, directed at the identification, screening and selection of a lead compound for future drug development. Discovery activities typically extend anywhere from 4-6 years in conventional pharmaceutical research and development timelines. Development activities, which follow, and which can take up to 7-10 years, are directed at demonstrating the safety, tolerability and clinical efficacy of the selected drug candidates. During the preclinical stage of the development process, a drug candidate is tested in vitro (typically on a cellular or sub-cellular level in a test tube or multi-well petri plate) and in vivo (in research models) to support planned or on-going human trials. The Company operates in three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). Through its RMS segment, it has been supplying research models to the drug development industry since 1947. It also provides a variety of related services that are designed to assist its clients in supporting the use of research models in drug discovery and development. Its DSA business segment provides services that enable its clients to outsource their drug discovery research, their critical, regulatory-required safety assessment testing and related drug discovery and development activities. Its Manufacturing segment helps to ensure the safe production and release of products manufactured by its clients. The Microbial Solutions (formerly known as Endotoxin and Microbial Detection or EMD) business provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals and consumer products. The Company's customers include biopharmaceutical companies, small and mid-sized pharmaceutical companies and biotechnology companies, and academic and government institutions. The Company competes in the marketplace based on therapeutic and scientific expertise in in vivo biology, quality, reputation, flexibility, responsiveness, pricing, innovation and capabilities. Its DSA segment competes with in-house departments of pharmaceutical and biotechnology companies, universities and teaching hospitals. The Company also competes with universities and teaching hospitals for outsourced services.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.